IOL Chemicals & Pharmaceuticals Share Price

NSE
IOLCP •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in IOL Chemicals & Pharmaceuticals
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W Low today
-10.7
TTM PE Ratio
Below industry Median
20
Price to Book Ratio
Low in industry
1.2
Dividend yield 1yr %
Below industry Median
1.2
TTM PEG Ratio
PEG TTM is negative
-0.5

IOL Chemicals & Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

IOL Chemicals & Pharmaceuticals Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
523.3 Cr
525.75 Cr
502.38 Cr
503.92 Cr
520.39 Cr

IOL Chemicals & Pharmaceuticals Yearly Revenue

Mar 2024Mar 2023Mar 2022
2162.86 Cr
2242.72 Cr
2216.06 Cr

IOL Chemicals & Pharmaceuticals Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
20.53 Cr
19.15 Cr
29.97 Cr
27.62 Cr
23.08 Cr

IOL Chemicals & Pharmaceuticals Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022
134.43 Cr
139.14 Cr
167.67 Cr
IOL Chemicals & Pharmaceuticals Result Highlights
  • IOL Chemicals & Pharmaceuticals Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 0.3%.

  • Its expenses for the quarter were down by 1.3% QoQ and up 0.6% YoY.

  • The net profit increased 7.2% QoQ and decreased 11.0% YoY.

  • The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 3.5 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

IOL Chemicals & Pharmaceuticals shareholding Pattern

Promoter
52.6%
Foreign Institutions
1.5%
Domestic Institutions
0.1%
Public
45.8%
Promoter
48.2%
Foreign Institutions
1.6%
Domestic Institutions
0.1%
Public
50.1%
Promoter
48.2%
Foreign Institutions
1.4%
Mutual Funds
0.1%
Domestic Institutions
0.1%
Public
50.3%
Promoter
48.2%
Foreign Institutions
1.4%
Mutual Funds
0.1%
Domestic Institutions
0.3%
Public
50.1%
Promoter
48.2%
Foreign Institutions
2.2%
Mutual Funds
0.1%
Domestic Institutions
0.4%
Public
49.3%
Promoter
48.2%
Foreign Institutions
2.3%
Domestic Institutions
0.4%
Public
49.1%

IOL Chemicals & Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
349.90
10Day EMA
358.10
12Day EMA
360.30
20Day EMA
367.50
26Day EMA
371.70
50Day EMA
382.70
100Day EMA
394.80
200Day EMA
403.80
5Day SMA
350.90
10Day SMA
364.50
20Day SMA
366.00
30Day SMA
377.20
50Day SMA
392.80
100Day SMA
397.70
150Day SMA
412.80
200Day SMA
407.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
65843 Rs
182512 Rs
Week Rs
90114 Rs
203752 Rs
Month Rs
84630 Rs
228578 Rs
Resistance & Support
339.08
Pivot
Resistance
First Resistance
347.22
Second Resistance
353.08
Third Resistance
361.22
Support
First Support
333.22
Second support
325.08
Third Support
319.22
Relative Strength Index
34.41
Money Flow Index
42.42
MACD
-11.39
MACD Signal
-9.13
Average True Range
14.76
Average Directional Index
21.51
Rate of Change (21)
-15.03
Rate of Change (125)
-21.91

IOL Chemicals & Pharmaceuticals Company background

Founded in: 1986
Managing director: Varinder Gupta
IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active PharmaceuticalIngredient (API) and specialty chemicals sectors. With substantive manufacturing capacities, the Company benefits from economiesof scale and cost supremacy. Its extensive expertise in both API and specialty chemicals strengthens its business model and opens doors to diversified growth opportunities.Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines. It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories.In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride. The Company is a leader in fostering green chemistry through its extensive production of Ethyl Acetate, a sustainable and environmentally friendly solvent. As one of the largest manufacturers globally, the Company plays a vital role in promoting the adoption of ecofriendly practices in various industries such as pharmaceuticals, printing, flexible packaging, adhesives, surface coatings, flavors, paints lamination, and essences.The company has two manufacturing units namely API Unit and Chemical Unit located in Punjab. API Unit manufactures Ibuprofen with the installed Capacity of 10 MTPD. Chemical Unit manufactures organic chemicals such as Glacial Acetic Acid, Ethyl Acetate, Acetic Anhydride, Mono chloro acetic Acid, Acetyl Chloride and Iso butyl Benzene. The company is having their presence in over 40 countries across the world, which includes Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt, and many others. They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy. DS Group, Cipla, Uflex Industries, ITC Ltd, ICI Paints, Asian Paints, Pidillte, Rallis India, Hindustan Polymide, Gujarat Super Phosphate and Avon Organics Ltd etc.The capacity enhancement project and Multi Product PPIs Plant and other pharmaceutical intermediate products with a CAPEX of Rs 130 crore was completed in 2012. The Company undertook another project of multi product plant for manufacture active pharmaceutical ingredients and upgrading of RD facilities involving a CAPEX of Rs 58.41 crore.G Drugs and Pharmaceuticals Limited (GDPL) was merged with Company, through The Board for Industrial and Financial Reconstruction (BIFR), vide its order dated 15 March 2012, with appointed date of 1 April 2010. The said Merger was made effective on 20 April 2012 and consequently GDPL ceased to exit from that date.During the current year 201617, the Company converted its existing multiple purpose plant into a dedicated ibuprofen manufacturing facility and resulting to its conversion, the ibuprofen manufacturing facility increased from 6200 TPA to 7200 TPA. During year 201718, Unit III to manufacture Fenofi brate, Clopidogrel and Lamotrigine Project was set up which costed Rs 16.48 crore. The company also setup Unit IV for manufacturing Metformin an antidiabetic drug with a capacity of 3000 MT per annum with project cost of Rs 10.02 crore. It enhanced installed capacity of Ibuprofen from 7200 TPA to 10000 TPA by debottlenecking and reengineering the plant in the month of August 2018.During year 2019, the Company has enhanced installed capacity of Metformin from 3,000 TPA to 4,000 TPA with a capex of Rs 2.71 crore it set up Unit V o manufacture Clopidogrel Bisulphate Fenofibrate with a capacity of 180 MT per annum with capex of Rs 19.26 crore it further enhanced existing manufacturing facilities of Ibuprofen from 10,000 TPA to 12,000 TPA and Iso Butyl Benzene from 9,000 TPA to 12,000 TPA in May 2019 with capex of Rs 12.10 crore. During 2020, the Company set up Unit VI, with an installed capacity of 240 MT per annum, which costed Rs 33.83 Crore, to manufacture Pantoprazole and has started its trial production. During 2021, the Company set up an another Unit7 for manufacturing Metformin with an additional capacity of 7,200 MT per annum for project costing Rs 28 cr. It installed new manufacturing facilities Unit8 to manufacture Ibuprofen Derivatives and other Pharma Products during FY 202021. It increased existing manufacturing facilities of Ethyl Acetate from 87,000 MT per annum to 100,000 MT per annum in Chemical segment during 202122.During the year 202223, IOL Foundation was incorporated as wholly owned subsidiary company. The Company set up multi product manufacturing facilities Unit 10 for manufacturing pharma APIs. It identified to manufacture Fenofibrate, Lamotrigine etc in this unit. Further, it also initiated the project for installation of new manufacturing facilities (Unit9) for manufacturing Gabapentin and other Pharma products during the year, which is under implementation.In 202324, Company commenced the production of Acetic Anhydride in the chemical division mainly for captive consumption as well as merchant sale with installed capacity of 25000 MTPA.
Read More

IOL Chemicals & Pharmaceuticals FAQs

IOL Chemicals & Pharmaceuticals share price is ₹331.75 in NSE and ₹331 in BSE as on 17/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

IOL Chemicals & Pharmaceuticals share price in the past 1-year return was -17.9. The IOL Chemicals & Pharmaceuticals share hit a 1-year low of Rs. 330.5 and a 1-year high of Rs. 537.7.

The market cap of IOL Chemicals & Pharmaceuticals is Rs. 2003.91 Cr. as of 17/2/2025 12:00:00 AM.

The PE ratios of IOL Chemicals & Pharmaceuticals is 20.51 as of 17/2/2025 12:00:00 AM.

The PB ratios of IOL Chemicals & Pharmaceuticals is 1.2 as of 17/2/2025 12:00:00 AM

The Mutual Fund Shareholding in IOL Chemicals & Pharmaceuticals was 0.02% at the end of 17/2/2025 12:00:00 AM.

You can easily buy IOL Chemicals & Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -